Moderna Dividend

Dividend criteria checks 0/6

Moderna does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.9%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$12.31
Dividend yield forecast in 3Y	0%

Recent dividend updates

No updates

Recent updates

Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 27

Moderna: Counting On Pipeline Too Much

Feb 23

Moderna: Highly Uncertain Future For mRNA Vaccine In A Post-Pandemic World

Feb 16

Moderna: Fade 2025 Outlook

Jan 15

Moderna, Inc. (NASDAQ:MRNA) Held Back By Insufficient Growth Even After Shares Climb 26%

Dec 29

Need To Know: The Consensus Just Cut Its Moderna, Inc. (NASDAQ:MRNA) Estimates For 2024

Nov 03

Moderna, Inc. (NASDAQ:MRNA) Shares Could Be 30% Below Their Intrinsic Value Estimate

Oct 18

Is Moderna, Inc. (NASDAQ:MRNA) Trading At A 47% Discount?

May 23

Weak Statutory Earnings May Not Tell The Whole Story For Moderna (NASDAQ:MRNA)

Mar 03

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if MRNA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MRNA's dividend payments have been increasing.

Dividend Yield vs Market

Moderna Dividend Yield vs Market

How does MRNA dividend yield compare to the market?
Segment	Dividend Yield
Company (MRNA)	n/a
Market Bottom 25% (US)	1.6%
Market Top 25% (US)	4.9%
Industry Average (Biotechs)	2.9%
Analyst forecast in 3 Years (MRNA)	0%

Notable Dividend: Unable to evaluate MRNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MRNA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate MRNA's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MRNA has not reported any payouts.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Moderna Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Moderna: Considering The Cancer Vaccine Angle

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Moderna Continues To Build A Pipeline

Insufficient new directors

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Co-Founder notifies of intention to sell stock

Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

President notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Moderna: Counting On Pipeline Too Much

Moderna, Inc., Annual General Meeting, May 06, 2024

Consensus EPS estimates fall by 12%

CEO & Director recently sold US$2.3m worth of stock

Moderna: Highly Uncertain Future For mRNA Vaccine In A Post-Pandemic World

Moderna, Inc. to Report Q4, 2023 Results on Feb 22, 2024

President notifies of intention to sell stock

Moderna: Fade 2025 Outlook

Moderna, Inc. Reiterates Earnings Guidance for the Year 2024, 2025 and 2026

President notifies of intention to sell stock

Moderna, Inc. (NASDAQ:MRNA) Held Back By Insufficient Growth Even After Shares Climb 26%

Moderna Announces Changes to Commercial Organization

Moderna Announces Changes to Commercial Organization

Consensus EPS estimates fall by 199%

Moderna, Inc. Provides Sales Guidance for the Year 2023

Need To Know: The Consensus Just Cut Its Moderna, Inc. (NASDAQ:MRNA) Estimates For 2024

Price target decreased by 11% to US$155

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine against Influenza and COVID-19

Moderna, Inc. (NASDAQ:MRNA) Shares Could Be 30% Below Their Intrinsic Value Estimate

Investor sentiment deteriorates as stock falls 17%

Moderna, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Co-Founder notifies of intention to sell stock

Moderna, Inc. Announces Positive Phase 1/2 Data from mRNA-1083, the company's Combination Vaccine Against Influenza and COVID-19

Moderna, Inc. Announces Ema Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's Updated Covid-19 Vaccine in the European Union

Moderna Receives U.S. FDA Approval for Updated Covid-19 Vaccine

Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against Ba.2.86

Investor sentiment improves as stock rises 21%

President notifies of intention to sell stock

Moderna Clinical Trial Data Confirm its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants

UMass Chan Medical School Announces Enrollment in Study to Explore Impact of Cytomegalovirus (CMV) Transmission in Early Education Settings

Consensus EPS estimates fall by 50%

Price target decreased by 7.2% to US$185

Moderna, Inc. Provides Sales Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Merck and Moderna, Inc. Initiate Phase 3 Study Evaluating V940 (Mrna-4157) in Combination with Keytruda(R) (Pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage Iib-Iv) Melanoma

Consensus EPS estimates fall by 12%

Moderna, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Moderna Announces Global Regulatory Submissions for its Respiratory Syncytial Virus (RSV) Vaccine, mRNA-1345

Moderna, Inc. Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine

Moderna, Inc.(NasdaqGS:MRNA) dropped from Russell Top 200 Growth Index

Moderna, Inc. Completes Submission of A Regulatory Application to the U.S. Food and Drug Administration for Its Updated COVID-19 Vaccine Containing Spike Proteins for the XBB.1.5 Sublineage of SARS-CoV-2

Consensus EPS estimates fall by 10%

Moderna and Merck Announces mRNA-4157 (V940) in Combination With KEYTRUDA Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA

Is Moderna, Inc. (NASDAQ:MRNA) Trading At A 47% Discount?

Consensus EPS estimates fall by 31%

First quarter 2023 earnings released: EPS: US$0.20 (vs US$9.10 in 1Q 2022)

Consensus EPS estimates upgraded to US$1.69 loss

CEO & Director exercised options and sold US$12m worth of stock

CEO & Director notifies of intention to sell stock

Weak Statutory Earnings May Not Tell The Whole Story For Moderna (NASDAQ:MRNA)

Consensus EPS estimates have been downgraded.

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies